News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
407,982 Results
Type
Article (21727)
Company Profile (135)
Press Release (386120)
Section
Business (126228)
Career Advice (977)
Deals (23793)
Drug Delivery (99)
Drug Development (58252)
Employer Resources (89)
FDA (11724)
Job Trends (9361)
News (223783)
Policy (20782)
Tag
2024 BioCapital Digital (9)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (5)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (2)
2024 Genetown Digital (3)
2024 Genetown Standard (4)
2024 Lone Star Bio Digital (4)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (3)
2025 BioForest Digital (4)
2025 Lone Star Bio Digital (4)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (943)
Accelerated approval (3)
Adcomms (17)
Allergies (49)
Alliances (31492)
ALS (62)
Alzheimer's disease (811)
Antibody-drug conjugate (ADC) (92)
Approvals (11724)
Artificial intelligence (159)
Autoimmune disease (15)
Automation (4)
Bankruptcy (227)
Best Places to Work (7050)
BIOSECURE Act (13)
Biosimilars (96)
Biotechnology (60)
Bladder cancer (46)
Brain cancer (19)
Breast cancer (150)
Cancer (1326)
Cardiovascular disease (122)
Career advice (797)
Career pathing (21)
CAR-T (72)
Cell therapy (211)
Cervical cancer (7)
Clinical research (48581)
Collaboration (526)
Compensation (205)
Complete response letters (24)
COVID-19 (1413)
CRISPR (24)
C-suite (153)
Cystic fibrosis (65)
Data (1398)
Decentralized trials (2)
Denatured (18)
Depression (25)
Diabetes (181)
Diagnostics (3106)
Digital health (8)
Diversity (7)
Diversity, equity & inclusion (23)
Drug discovery (81)
Drug pricing (110)
Drug shortages (30)
Duchenne muscular dystrophy (62)
Earnings (51913)
Editorial (29)
Employer branding (13)
Employer resources (82)
Events (59127)
Executive appointments (470)
FDA (12534)
Featured Employer (26)
Friedreich's ataxia (3)
Frontotemporal dementia (2)
Funding (371)
Gene editing (58)
Generative AI (18)
Gene therapy (168)
GLP-1 (599)
Government (2139)
Grass and pollen (2)
Guidances (37)
Healthcare (8553)
Huntington's disease (13)
IgA nephropathy (20)
Immunology and inflammation (84)
Indications (19)
Infectious disease (1509)
Inflammatory bowel disease (102)
Inflation Reduction Act (8)
Influenza (31)
Intellectual property (71)
Interviews (135)
IPO (10374)
IRA (45)
Job creations (2630)
Job search strategy (716)
Kidney cancer (7)
Labor market (21)
Layoffs (289)
Leadership (13)
Legal (4760)
Liver cancer (41)
Lung cancer (195)
Lymphoma (100)
Machine learning (2)
Management (34)
Manufacturing (209)
MASH (53)
Medical device (5816)
Medtech (5819)
Mergers & acquisitions (13784)
Metabolic disorders (539)
Multiple sclerosis (56)
NASH (20)
Neurodegenerative disease (54)
Neuropsychiatric disorders (22)
Neuroscience (1164)
NextGen: Class of 2025 (3081)
Non-profit (1159)
Northern California (1446)
Now hiring (20)
Obesity (312)
Opinion (190)
Ovarian cancer (46)
Pain (75)
Pancreatic cancer (43)
Parkinson's disease (107)
Partnered (11)
Patents (172)
Patient recruitment (57)
Peanut (24)
People (37267)
Pharmaceutical (75)
Pharmacy benefit managers (21)
Phase I (15121)
Phase II (20899)
Phase III (16482)
Pipeline (855)
Podcasts (69)
Policy (103)
Postmarket research (1746)
Preclinical (5499)
Press Release (29)
Prostate cancer (70)
Psychedelics (19)
Radiopharmaceuticals (174)
Rare diseases (266)
Real estate (3501)
Recruiting (31)
Regulatory (15213)
Reports (24)
Research institute (986)
Resumes & cover letters (153)
Rett syndrome (4)
RNA editing (2)
RSV (29)
Schizophrenia (60)
Series A (64)
Series B (37)
Service/supplier (7)
Sickle cell disease (40)
Southern California (1407)
Special edition (16)
Spinal muscular atrophy (112)
Sponsored (15)
Startups (2183)
State (2)
Stomach cancer (9)
Supply chain (53)
The Weekly (49)
United States (13608)
Vaccines (338)
Venture capitalists (27)
Webinars (11)
Weight loss (240)
Women's health (19)
Worklife (7)
Date
Today (81)
Last 7 days (494)
Last 30 days (1901)
Last 365 days (22395)
2025 (5538)
2024 (23325)
2023 (25954)
2022 (32892)
2021 (33796)
2020 (31609)
2019 (24804)
2018 (19242)
2017 (21194)
2016 (19384)
2015 (23066)
2014 (17814)
2013 (14646)
2012 (15719)
2011 (16143)
2010 (14855)
Location
Africa (449)
Alabama (34)
Alaska (2)
Arizona (80)
Arkansas (9)
Asia (26994)
Australia (3708)
California (3436)
Canada (1176)
China (323)
Colorado (160)
Connecticut (150)
Delaware (88)
Europe (56854)
Florida (573)
Georgia (114)
Idaho (17)
Illinois (303)
India (21)
Indiana (214)
Iowa (3)
Japan (117)
Kansas (68)
Kentucky (18)
Louisiana (1)
Maine (40)
Maryland (527)
Massachusetts (2678)
Michigan (91)
Minnesota (201)
Mississippi (2)
Missouri (35)
Montana (17)
Nebraska (12)
Nevada (38)
New Hampshire (25)
New Jersey (1182)
New Mexico (21)
New York (1057)
North Carolina (634)
North Dakota (3)
Northern California (1446)
Ohio (123)
Oklahoma (5)
Oregon (22)
Pennsylvania (815)
Puerto Rico (10)
Rhode Island (17)
South America (653)
South Carolina (10)
Southern California (1407)
Tennessee (49)
Texas (550)
Utah (115)
Virginia (101)
Washington D.C. (43)
Washington State (314)
West Virginia (2)
Wisconsin (33)
407,982 Results for "solasia pharma k k".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Opinion
Biosimilars Shouldn’t Be This Hard To Bring to Market
Biosimilars are essential healthcare equalizers, but their regulation is overly complicated due to lobbying by makers of branded biologics looking to maintain blockbuster revenue.
March 24, 2025
·
7 min read
·
Sarfaraz K. Niazi
Deals
Lilly Drops Up to $2.5B for Scorpion’s PI3K-inhibitor Molecule
The multi-billion deal, in which Eli Lilly will acquire Scorpion Therapeutics’ STX-478 program, is a shot in the arm for PI3K treatments, which have had a mixed history over the past few years.
January 13, 2025
·
2 min read
·
Dan Samorodnitsky
Press Releases
BeyondSpring Files 2024 Annual Report on Form 10-K
March 28, 2025
·
2 min read
Press Releases
Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K
March 19, 2025
·
2 min read
Clinical research
Pharma R&D Returns Grow Again, But Deloitte Warns Progress is ‘Fragile’
Deloitte urged pharma executives to “be bold” in a new report tracking the top 20 pharmaceutical companies’ R&D performance.
March 27, 2025
·
3 min read
·
Annalee Armstrong
Press Releases
Aurora Spine Announces FDA 510(k) Clearance for the AERO™ Facet Fusion System
March 26, 2025
·
3 min read
Press Releases
Sonoma Pharmaceuticals Secures Extensive U.K. Regulatory Clearances of Key Wound Care and Dermatology Products by the Medicines & Healthcare Products Regulatory Agency (MHRA)
March 11, 2025
·
3 min read
Press Releases
Sibel Health Announces Close of New Series C Financing and New FDA 510(k) Clearance
March 20, 2025
·
3 min read
Press Releases
Monogram Technologies Announces FDA 510(k) Clearance for the Monogram mBôsTM TKA System
March 17, 2025
·
8 min read
Approvals
Roche Wins First-Line Breast Cancer Nod for Oral PI3K Blocker, Projects $2.3B in Peak Sales
With the regulatory approval for advanced breast cancer, Roche’s inavolisib is a potential challenger to Novartis’ PI3K inhibitor Piqray, which last year generated $505 million in revenue.
October 11, 2024
·
2 min read
·
Tristan Manalac
1 of 40,799
Next
